Analyzing Upstream Bio (UPB) and Its Peers

Upstream Bio (NASDAQ:UPB) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare Upstream Bio to similar businesses based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Upstream Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1	0	3	0	2.50
Upstream Bio Competitors	6074	12278	37794	1182	2.59

Upstream Bio presently has a consensus price target of $43.33, indicating a potential upside of 56.21%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.63%. Given Upstream Bio’s higher probable upside, analysts clearly believe Upstream Bio is more favorable than its peers.

Insider and Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 13.6% of Upstream Bio shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Upstream Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,366.77%	-28.71%	-27.94%
Upstream Bio Competitors	-906.16%	-572.36%	-29.72%

Volatility & Risk

Upstream Bio has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Upstream Bio’s peers have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares Upstream Bio and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Upstream Bio	$2.37 million	-$62.81 million	-14.76
Upstream Bio Competitors	$888.58 million	-$44.34 million	11.03

Upstream Bio’s peers have higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Upstream Bio peers beat Upstream Bio on 8 of the 13 factors compared.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.